NF-κB proteins play a central and subunit-specific role in the response to DNA damage. Previous work identified p50/NF-κB1 as being necessary for cytotoxicity in response to DNA alkylation damage. Given the importance of damage-induced cell death for the maintenance of genomic stability, we examined whether Nfkb1 acts as a tumor suppressor in the setting of alkylation damage. Hprt mutation analysis demonstrates that Nfkb1 −/− cells accumulate more alkylator-induced, but not ionizing radiation (IR)-induced, mutations than similarly treated wild-type cells. Subsequent in vivo tumor induction studies reveal that following alkylator treatment, but not IR, Nfkb1 −/− mice develop more lymphomas than similarly treated Nfkb1 +/+ animals. Heterozygous mice develop lymphomas at an intermediate rate and retain functional p50 in their tumors, indicating that Nfkb1 acts in a haploinsufficient manner. Analysis of human cancers, including therapy-related myeloid neoplasms, demonstrates that NFKB1 mRNA expression is downregulated compared with control samples in multiple hematological malignancies. These data indicate that Nfkb1 is a haploinsufficient, pathway-specific tumor suppressor that prevents the development of hematologic malignancy in the setting of alkylation damage.
INTRODUCTION
Damage to DNA is a central factor in the acquisition of genomic errors and development of cancer. Chemotherapy represents an exogenous source of DNA damage that is highly genotoxic. Therapy-related myeloid neoplasia (t-MN) is a devastating complication of cytotoxic chemotherapy whereby a secondary malignancy is induced following treatment of an initial malignant or nonmalignant disease. 1 The importance of DNA alkylation damage to secondary malignancy formation is underlined by the observation that in the largest study of t-MN reported to date, 78% of patients received an alkylating agent for their primary tumor. 2 NF-κB represents a family of proteins that comprises five subunits: p50 (NF-κB1, p105), p52 (NF-κB2, p100), p65 (relA), c-rel and relB, which play a complex role in tumor formation. Although the oncogenic effects of this transcription factor are consistent with the propensity of NF-κB to mediate survival signaling, 3, 4 tumor-suppressive actions are evident in the finding that various subunits can indirectly mediate the tumor-suppressive effects of p53 or ARF. [5] [6] [7] [8] [9] Despite indirect tumor suppression, targeted deletion of individual NF-κB proteins has not yet revealed a direct tumor-suppressive role for any specific subunit. 10 We recently reported that p50/NF-κB1 is necessary for cytotoxicity by alkylating agents such as temozolomide (TMZ) or N-methyl-N-nitrosourea (MNU). 11 These agents induce cell death by forming O 6 -methylguanine lesions that mispair with deoxythymidine residues and induce cytotoxicity in a mismatch repair-dependent manner. 12 In cells where damage is tolerated, O 6 -methylguanine:deoxythymidine mismatches lead to mutations that are potentially oncogenic. 13 Given that depletion of p50, or deletion of Nfkb1, renders cells tolerant of alkylation damage without affecting damage repair, 11 we hypothesized that this NF-κB subunit acts to maintain genomic stability specifically in the setting of DNA alkylation damage. In this report, we demonstrate that Nfkb1 protects mice against alkylator-induced, but not ionizing radiation (IR)-induced, lymphoma formation in a haploinsufficient manner.
RESULTS AND DISCUSSION
Alkylating agents are mutagenic and loss of p50/Nfkb1 leads to increased survival following alkylator treatment. 11 These findings suggest that loss of Nfkb1 may affect alkylator-induced mutagenesis. To examine mutation formation, the hypoxanthine-guanine phospho-ribosyltransferase (hprt) assay was used in Nfkb1 −/− and Nfkb1 +/+ mouse embryonic fibroblasts (MEFs). This assay accurately reports alkylator-induced mutations. Primary, low passage MEFs were treated with the alkylating agent and mutation induction was assessed. Significantly more 6-TG-resistant clones develop following treatment of Nfkb1 −/− than Nfkb1 +/+ MEFs (P o 0.03, Figure 1a ), suggesting that Nfkb1 maintains genomic integrity in the setting of alkylation damage. it is specifically p50, the mature protein product of Nfkb1, that prevents mutation induction, Hprt assay was performed following re-expression of p50. Nfkb1 −/− MEFs stably expressing p50 acquire less 6-TG-resistant clones following alkylator treatment than isogenic cells expressing empty vector (EV) ( Figure 1b ). Next, to examine DNA strand break induction, alkaline comet assay was performed following treatment. Equal amounts of strand breaks are induced in Nfkb1 +/+ and Nfkb1 −/− MEFs within 3 h of treatment ( Figure 1c ). This finding suggests that the difference in the mutation frequency following alkylator exposure is not due to quantitative differences in the level of induced DNA damage, a finding supported by previous data showing that loss of Nfkb1 does not affect damage repair. 11 The above observations, coupled with the finding that loss of Nfkb1 results in a decrease in alkylation-induced apoptosis, 11 suggest that the difference in mutagenesis is likely due to increased survival of damaged Nfkb1 −/− compared with Nfkb1 +/+ MEFs.
Increase in mutation formation suggests that Nfkb1 may be tumor suppressive in the setting of DNA damage. To examine this hypothesis, we attempted to transform MEFs using TMZ or MNU, but found that primary cells of both genotypes are resistant to alkylator-induced transformation in vitro. Therefore, in vivo tumor formation was examined using Nfkb1 +/+ and Nfkb1 −/− mice. MNU was used as the inducing carcinogen because of its well-described tumor-forming dose-response profile. 14, 15 Six-week old Nfkb1 −/− and Nfkb1 +/+ mice were injected with either vehicle or MNU and followed for 1 year. At each MNU concentration, significantly more Nfkb1 −/− than Nfkb1 +/+ mice develop thymic lymphomas (P o 0.002 at 30 mg/kg and P o0.02 at 15 mg/kg) ( Figure 2a ). Next, to examine potential Nfkb1 gene-dosage effects, Nfkb1 −/− animals, backcrossed for 12 generations with C57BL/6 mice, were obtained and bred with wild-type C57BL/6 animals. Subsequently, Nfkb1 −/− , Nfkb1 +/ − and Nfkb1 +/+ mice were injected with 50 mg/kg MNU. At this higher MNU concentration, Nfkb1 −/− mice also form significantly more thymic lymphomas than Nfkb1 +/+ animals (P o 0.0001) ( Figure 2b and Supplementary Figure 1 The carcinogenic effect of MNU is blocked primarily by O 6 -methylguanine-DNA methyltransferase (MGMT), a protein that specifically removes alkyl groups from the O 6 position of guanine. 15 Therefore, MGMT expression level was examined in Hprt assay in (a) was performed using early passage primary MEFs, harvested from day 14 embryos, treated with TMZ and maintained in exponential growth for 7 days. Cells were subcultured in growth medium alone (plating efficiency) or in the presence of 5 μg/ml 6-TG for selection of mutants. Induced Hprt mutations were calculated as the number of 6-TG-resistant colonies per 10 6 cells plated after correction for plating efficiency. Importantly, 5 μg/ml 6-TG is 100% lethal to un-mutated MEFs of both genotypes. For re-expression of p50, immortal Nfkb1 −/− MEFs were infected with the retroviral vector MigR1-p50 or MigR1-EV. MigR1-p50 was created by liberating p50 from pcDNA3.1-p50 33 by digestion with PmeI and XhoI, and ligated into the BglII site of pMSCV-MigR1 containing an IRES-GFP insert. Retrovirus was produced with Platinum-GP packaging cells following transfection of MigR1-p50 or MigR1-EV using XtremeGENE transfection reagent (Roche, Indianapolis, IN, USA). MEFs were then spinoculated with virus/polybrene-containing supernatant and colonies sorted by FACS. Alkaline single-cell gel electrophoresis (Comet assay) was performed as described. 34 Briefly, MEFs were treated with TMZ for 3 h, trypsinized and resuspended in low-melting-point agarose. A single-cell suspension in the agarose was layered on glass slides and, following cell lysis, submerged in alkaline (pH413) buffer and electrophoresis performed until a slight migration pattern was observed in the untreated nuclei. Dried slides were stained with ethidium bromide and visualized by fluorescence microscopy. Tail length was quantified as tail length normalized to nuclear diameter. untreated mice. Equal MGMT protein expression is seen in thymic tissue from Nfkb1 −/− and Nfkb1 +/+ animals (Figure 2c ), suggesting that the difference in tumor-formation rates is not due to differences in O 6 -methylguanine repair. In addition, given that Nfkb1 −/− animals have defects in innate and adaptive immunity, 10, 16 we examined whether tumors from Nfkb1 −/− animals can be transplanted into mice of both genotypes. Nfkb1 −/− and Nfkb1 +/+ recipient mice develop disseminated cancer at equal rates following injection of tumor cells from Nfkb1 −/− animals ( Supplementary Figure 2) , indicating that Nfkb1 −/− tumors are equally transplantable.
It was previously noted that loss of Nfkb1 does not affect the cytotoxic response to IR. 11 We therefore examined tumor formation in response to whole-body IR. Remarkably, at the IR dose used, no significant difference in tumor formation rate is noted between Nfkb1 −/− and Nfkb1 +/+ animals (P40.5) ( Figure 2d ). Although these data suggest that Nfkb1 does not protect mice from IR-induced tumor formation, it is possible that at a different dose of IR, or if greater numbers of animals are used, a difference in tumor formation may be noted. Nevertheless, given that the dose of IR used results in~30% tumor formation in both genotypes, a rate comparable to that induced by 30 mg/kg MNU in Nfkb1 +/+ mice (Figure 2a ), it is evident that loss of Nfkb1 renders animals significantly more sensitive to tumor formation by MNU than IR. Given the findings in response to IR, we also examined mutation induction following IR. In contrast to TMZ, expression of p50 does not affect mutation frequency in response to IR (Figure 2e ). Together, these findings indicate that loss of Nfkb1 leads to an increase in the susceptibility of mice to alkylationinduced tumor formation and, moreover, suggest that Nfkb1 acts as a pathway-specific tumor suppressor.
To examine whether Nfkb1 functions in a haploinsufficient manner, tumors from mice were harvested. All the tumors from Nfkb1 +/ − animals retain an Nfkb1 allele ( Figure 3a ). As loss of heterozygosity can also occur via posttranslational mechanisms, expression of p105 and p50 was examined. In tumors from Nfkb1 +/ − animals, both p105 and p50 expression are universally retained (Figure 3b ). Moreover, immunohistochemical analysis demonstrates that p50 is found in tumor cells from Nfkb1 +/ − mice and not solely in the stroma (Figure 3c ). Finally, to examine the functional status of p50, binding to κB consensus DNA was evaluated using electrophoretic mobility shift assay (EMSA). Nfkb1 Six-week-old mice were given a single i.p. injection of MNU or vehicle. For radiation carcinogenesis, equal ratios of male to female animals were treated with four weekly doses of 1 Gy total body irradiation using a Phillips RT250 X-ray generator. Animals were observed at least two times per week and killed when they exhibited signs of cachexia, hunched position, respiratory distress or a visible mass. Following euthanasia, autopsy was performed. For evaluation of thymic MGMT expression, 5-8-week-old male C57BL/6 mice were killed and the thymus harvested. Immunoblot was performed on cell lysates with anti-MGMT antibody (sc-8828, Santa Cruz Biotechnology, Dallas, TX, USA). For histological analysis, tumors were removed and either snap-frozen, disaggregated for FACS analysis or immersed in paraformaldyhyde prior to sectioning. Statistical analysis was performed using one-sided Mantel-Cox log rank analysis.
Protein from three tumors of each genotype was harvested and examined for subunit binding by supershift analysis. In addition to p50 binding, p52 was examined as this subunit most often crosscompensates when p50 is lost, 11, 17 and p65 was studied as this is the primary interacting partner of p50. Supershift analysis demonstrates that although tumors from Nfkb1 +/+ animals contain p50/p65 dimers, in Nfkb1 −/− mice although p65 remains, p50 binding is lost and replaced by p52 ( Figure 3d ). Most significantly, tumors from Nfkb1 +/ − animals retain p50 that binds DNA. These findings indicate that functional p50, that is, p50 that does not contain mutations in critical DNA-binding regions, is maintained in tumors from heterozygous mice and, when considered with the intermediate tumor formation rate in heterozygote animals (Figure 2b) , suggest that Nfkb1 is a haploinsufficient tumor suppressor. Tumor suppression by Nfkb1 raises the question of whether this subunit acts in a similar manner in man. Although NFKB1 is rarely mutated in human tumors, the haploinsufficient nature of this factor suggests that reduced expression may be sufficient to facilitate tumor formation. We therefore analyzed NFKB1 expression data in T-cell lymphomas and noted that 100% of tumors have at least twofold decreased expression relative to CD8 + and CD4 + T cells from normal human peripheral blood (Figure 4a ). 18 Next, a series of other tumors were studied and a highly significant decrease in NFKB1 expression noted in multiple hematological malignancies (P o 1 × 10 − 7 ), including B-cell acute lymphoblastic leukemia (ALL) (Figure 4b) , T-cell ALL ( Supplementary Figure 3a) , 19 B-cell CLL (Figure 4c and Supplementary Figure 3b ), 20,21 diffuse large B-cell lymphoma (DLBCL) (Supplementary Figure 3c) 22 and AML (Figure 4d ). 19 In addition, P65 expression level was examined. Contrary to NFKB1, P65 expression is upregulated in T-cell ALL (2.3fold), B-cell ALL (1.6-fold) and AML (1.5-fold) ( Supplementary  Figure 4a) , decreased in T-cell lymphoma (Supplementary Figure  4b) and unchanged in DLBCL ( Supplementary Figure 4c ), suggesting that a general decrease in NF-κB pathway mRNA is not present. The above data demonstrate that in multiple different Genotyping was performed using snap-frozen tumor samples following thawing and lysis at 55°C for 18 h. Nucleic acid was extracted and DNA amplified by PCR using primers described for Nfkb1 −/− animals (Jackson Laboratory). Amplified DNA was run through 2% agarose gel. For tumor protein, snap-frozen samples were thawed, homogenized in 700 ml RIPA lysis buffer and incubated on ice for 5 min. Subsequently, samples were centrifuged (14000 g × 5 min) and the supernatant used for immunoblotting and EMSA. Immunoblots were performed with anti-p105 C-terminal (#4717, Cell Signaling Technologies), anti-p50 (sc-8414, Santa Cruz Biotechnology), anti-actin (sc-7210) or anti-gapdh (sc-137179) antibodies. EMSA was performed as previously described 11 using a probe bearing the decameric Ig-κB consensus sequence (5′-GGGACTTTCC-3′). SS was performed by pre-incubation with anti-p50 (sc-1190x), anti-p52 (sc-298x) or anti-p65 (sc-8008) antibodies for 30 min on ice.
Nfkb1 and tumor suppression human hematological malignancies a striking decrease in NFKB1 mRNA expression is apparent.
Given that Nfkb1 is tumor suppressive specifically following alkylator treatment and that over 75% of t-MN patients receive an alkylating agent for their primary tumor, 2 NFKB1 expression was examined in t-MN. We performed next-generation RNA sequencing on a series of patients with t-MN and NFKB1 expression level was compared with that in samples from patients with de novo AML, which occurs without a history of prior malignancy. t-MN samples have significantly reduced NFKB1 relative to that found in de novo AML (P = 0.026, Figure 4e ). Although t-MN has a higher frequency of adverse-risk cytogenetics (for example, − 5/del(5q) and − 7/del(7q)), 2 NFKB1 expression in patients with adverse-risk cytogenetics is also decreased compared with de novo AML with similar karyotypes (17.68 ± 0.18 sterr, n = 14 vs 18.17 ± 0.20, n = 5). Although this smaller subset does not achieve statistical significance (P = 0.19), the median values in the subgroups are comparable to those in the complete sample sets. Finally, to examine whether mRNA differences in de novo AML and t-MN patients are reflected by differences in protein expression, immunoblotting was performed on the original bone marrow samples from patients with both types of disease. A general trend for less p50 protein is seen in t-MN samples compared with de novo AML, an observation confirmed by densitometry following normalization to loading (Figure 4f and Supplementary Figure 4d ). Importantly, t-MN samples also have less p105, supporting the observation that NFKB1 expression is reduced at the mRNA level in these tumors. In addition, it is notable that in myeloid neoplasms decreased NFKB1 expression is associated with significantly reduced expression of death pathway genes (Supplementary Figure 5 ), supporting the association of reduced NFκB1 with increased damage tolerance and cell survival. In sum, the human data are consistent with the animal findings and suggest that chemotherapy exposure and reduced NF-κB1 cooperate to promote malignancy. Oncomine (Compendia Bioscience, Ann Arbor, MI, USA) was initially used for screening of data and preliminary analysis. Subsequently, identified datasets (GEO accession: GSE7186; 19 GSE2466; 20 and GSE6338 18 ) were downloaded from the Gene Expression Omnibus using the Bioconductor package GEOquery. 36, 37 Data for DLBCL by Rosenwald et al. 22 were downloaded from the Lymphoma/Leukemia Molecular Profiling Project Gateway (http://llmpp.nih.gov/DLBCL/). Data were quantile normalized and log2 transformed as needed using the limma and lumi packages. 38 The median NFKB1 expression level of control samples was calculated, and the percentage of tumor samples with twofold lower expression determined. Means and standard deviations of NFKB1 log2 normalized expression or log2 median centered ratios for patient samples and controls in each dataset were calculated using Graphpad Prism (San Diego, CA, USA). Five t-MN samples were processed for next-generation RNA sequencing on the Illumina platform as previously described. 35 Patient characteristics and read depth are provided (Supplementary Table 1 ). Data analysis and expression level estimates were performed as previously described. 35 All primary sequencing data will be made publicly available in dbGAP, accession number phs000759.v1.p1. Two-tailed Student's t tests were used with an alpha of o0.05. For t-MN, onesided Wilcoxon rank sum test was used. For immunoblotting, bone marrow samples were thawed, washed in PBS and lysed with RIPA buffer prior to SDS-PAGE and immunoblotting. Anti-lamin B antibody (sc-6216). p50 quantification was performed by densitometry by measuring band intensity with ImageJ freeware (WS Rasband, National Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/) and the data were plotted as ratio over loading after compensating for background intensity taken in a non-immunoreactive region of the blot.
The current work uncovers a previously unidentified tumorsuppressive role for Nfkb1. Specifically, loss of Nfkb1 increases the susceptibility of animals to alkylator-induced lymphoma formation. Interestingly, tumor formation in response to IR is not increased, suggesting that Nfkb1 mediates its tumor-suppressive effects in a pathway-specific manner. Pathway-specific tumor suppression is consistent with the prior finding that the mature product of Nfkb1, p50, facilitates cytotoxicity specifically in response to certain types of DNA damage. 11 Moreover, the observation that Nfkb1 −/− animals do not have increased susceptibility to tumor formation by the carcinogen, diethylnitrosamine, 23 an agent that induces tumors by forming O 4 -ethylthymidine adducts, further emphasizes the damagespecific nature of tumor suppression by Nfkb1. Despite tumor suppression, it is notable that Nfkb1 −/− animals are not tumor prone at baseline. 16 Although lack of spontaneous tumor formation in animals deficient for a tumor suppressor is not uncommon, 24 the absence of increased tumorigenesis may be related to the fact that Nfkb1 −/− animals are housed in a pathogen-free environment. The primary phenotype of Nfkb1 −/− mice is their deficiency in innate and adaptive immunity. 10, 16 Although alterations in the inflammatory environment likely contribute to tumor formation, the damage-specific nature of tumor suppression, coupled with the increased mutagenesis in vitro, argues against tumor suppression by Nfkb1 being solely an immune-mediated phenomenon.
The data suggest that tumor suppression occurs in a haploinsufficient manner, indicating that reduced expression, without complete loss, is sufficient to facilitate oncogenesis. This observation is supported by prior work indicating that even partial decrease in p50/p105 is sufficient to compromise the damage response. 11 From a mechanistic prospective, a decrease in p50 level results in formation of compensatory p52/p65 heterodimers, as noted on EMSA in the tumor tissue ( Figure 3d ). Although p52 can cross-compensate for p50 in certain respects, 17 it cannot functionally compensate for p50 in the response to DNA damage. 11 Haploinsufficiency is particularly relevant to man because complete loss of NFKB1/p50 in human tumors is rare, likely because of the critical role of NF-κB in normal cellular physiology. The lack of significant NFKB1 gene deletion or mutation in cancer raises the question of how NFKB1 expression is reduced in human malignancy. Although decreased expression may be a result of epigenetic factors such as promoter methylation, several oncogenes implicated in hematological malignancy, including tal1, lmo1, bcl-6 and myc, negatively regulate Nfkb1 expression. [25] [26] [27] On the other hand, low NFKB1 expression may be a normal variant found in the general population, an observation supported by the description of a functional NFKB1 promoter polymorphism, -94ins/delATTG, that is associated with reduced NFKB1 expression. 28 Therapy-related malignancy is a particularly severe complication of cancer treatment that is becoming more prevalent as patients survive for longer time. 1 In fact, up to one in six cancers is thought to be therapy-related. 29 Many chemotherapeutic agents that induce t-MN have mechanisms of action that involve the NF-κB1/ p50 pathway. From a clinical perspective, NFKB1 expression, like other predisposing factors, may be especially important in patients with nonmalignant lesions where the risk/benefit ratio for treatment with a cytotoxic agent can be unclear. In patients who have a higher risk of secondary tumor formation, caution should be taken prior to the use of a cytotoxic agent whose beneficial effects may be slim. In this regard, therapy-related lymphoma was recently reported in several patients with lowgrade gliomas that were treated with an alkylator. 30 The ability to maintain genomic integrity in the face of DNA damage is a feature of 'caretaker' genes; 31 however, NF-κB1 does not appear to be directly involved in damage repair. Nevertheless, Nfkb1 is tumor suppressive in the setting of DNA damage.
These observations suggest that NF-κB1 may belong to the growing group of low-penetrance cancer susceptibility genes that act in combination to determine the overall cellular response to genomic insults. 32 Future work will examine the mechanism by which this ubiquitous, yet under-examined, NF-κB subunit modulates the response to DNA damage.
